FdaApplication
NDA 218709
Identifiers
- fda_app_no: NDA218709
Properties
| Property | Value |
|---|---|
| applicant_name | X4 PHARMACEUTICALS INC |
| application_type | NDA |
| approval_date | 2024-04-26 |
Revenue by product
XOLREMDI
| Period | Revenue |
|---|---|
| Q4 2024 | $1.5M† |
| Q3 2024 | $0.6M† |
| Q2 2024 | $0.6M† |
| Q4 2023 | $0.0M† |
| Q3 2023 | $0.0M† |
| Q2 2023 | $0.0M† |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one. A figure marked † is the company's one reported revenue line rather than a product breakdown.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| XOLREMDI | MAVORIXAFOR | 100MG | CAPSULE;ORAL |
1 product